CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced the appointment of Ms. Geneviève Lemaire, currently Interim Corporate Controller, to serve as the Company’s Vice President, Finance and Chief Accounting Officer. Ms. Lemaire is a chartered professional accountant in Canada and Certified Public Accountant, registered in the State of Illinois. She has worked in various accounting and audit functions for Ernst & Young in Canada and Switzerland and in senior finance and accounting functions in other organizations. Ms. Lemaire will be the principal financial officer overseeing the completion and filing of the Company’s 2015 annual audited consolidated financial statements and the related documents and filings, while also providing the overall leadership in the finance and accounting function within the Company.
The Company also announces that Mr. Keith Santorelli, the Company’s former Vice President, Finance and Chief Accounting Officer, has left the Company to pursue other opportunities. Mr. Santorelli served as the Company’s principal financial officer after the Company’s reorganization of its finance and accounting function was implemented in early October 2015.
Mr. David A. Dodd, Chairman, President and Chief Executive Officer of the Company, commented on the developments, stating, “I would like to thank Keith for serving the Company well during its period of transition. I am looking forward to working with Geneviève more closely as she helps us transition our finance and accounting operation to our Charleston office. Geneviève has a great deal of knowledge of the Company as she has been serving, on a contract basis, as our Interim Corporate Controller since last August. She will continue to serve on a contract basis in her new position while we staff our finance and accounting function in Charleston on a permanent basis.”
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition or license of products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.